IFT20 protein’s role in helping cancer cells to invade – Medical Xpress

February 9, 2017 The functions of Ror2 and IFT20 in invasive cancer cells. In healthy cells IFT20 regulates the formation and function of primary cilia. Many cancer cells lack cilia, and these cells induce and sustain the expression of IFT20 through the high expression of Ror2. IFT20 promotes the formation of Golgi-derived microtubules by binding with the GM130-AKAP450 complex in Golgi. By doing this it regulates the deployment of Golgi and transport of proteins within Golgi, both important parts of the formation of invadopodia. Credit: Kobe University

An international research team has discovered that the IFT20 protein helps some cancer cells to invade by facilitating the transportation of membranes and proteins within parts of the cell.

Primary cilia exist on the surface of almost all human cells, acting as "cell antenna" that receive information from outside the cell. IFT20 (intraflagellar transport 20) is a protein present in most human cells that plays an essential role in the formation and functions of these primary cilia. In healthy cells it acts as a "cargo adaptor" to transport proteins along microtubules within cilia, but many cells lose these cilia when they become cancerous. This research has shed light on the function of IFT20 in non-ciliated cancer cells for the first time. The discovery has potential applications for developing new cancer treatment methods that block invasive cancer cells by targeting IFT20. The findings were published on January 26 in the online edition of Scientific Reports.

This research was carried out by an international team including Associate Professor NISHITA Michiru (Kobe University Graduate School of Medicine Department of Physiology and Cell Biology), Professor MINAMI Yasuhiro (Kobe University Graduate School of Medicine, Department of Physiology and Cell Biology), Professor Victor W. Hsu (Harvard Medical School) and Professor Gregory J. Pazour (University of Massachusetts Medical School). Most cancer-related deaths are said to be caused by cell invasion and the consequent spread of cancer cells to other parts of the body (metastasis). To counter this, scientists are searching for the mechanism that controls the invasive properties of cancer cells.

Researchers already knew that a cell membrane protein known as Ror2 expresses highly in various cancer cells, and it promotes cancer cell invasion and metastasis. Professor Nishita's team investigated various kinds of non-ciliated cancer cells and discovered that Ror2 promoted cancer cell invasiveness by inducing the expression of IFT20.

Many tumor cells break through the barrier of the extracellular matrix and infiltrate their surroundings by forming protruding structures known as invadopodia (see figure). The formation of invadopodia requires membranes and proteins supplied by the intracellular transport system, using the Golgi complex. The Golgi complex must be close to invadopodia to deploy these materials. The team's findings demonstrate that in tumor cells, IFT20 induces the Golgi complex to form microtubules by promoting interaction between the Golgi proteins GM130 and AKAP450. It also regulates the structure of the Golgi complex and transport of proteins within the complex. "This research has clarified a new molecular mechanism related to the formation of Golgi-derived microtubules, and its important role in invasive cancer cells," said Professor Nishita.

The relationship between loss of cilia and a cell's cancerous properties remains unclear. IFT20 is involved in the formation and function of cilia in healthy cells, but in non-ciliated cancer cells it is now clear that IFT20 is responsible for the formation of invadopodia. By continuing to analyze the relationship between IFT20 and the loss of cilia, this line of research could help shed light on the fundamental question of why many cancer cells lack cilia. Additionally, if the specific regulatory mechanism of IFT20 in cancer cells is revealed, this knowledge could be used to develop treatment that targets IFT20 to block invasive cancer cells.

Explore further: Study reveals gene's role in male infertility

More information: Michiru Nishita et al, Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness, Scientific Reports (2017). DOI: 10.1038/s41598-016-0028-x

Journal reference: Scientific Reports

Provided by: Kobe University

A Virginia Commonwealth University-led research team has opened a fresh direction in the field of male infertility with a new study that examines the role of a particular gene in the formation of sperm flagella, which is ...

A cellular component known as the Golgi apparatus may play a role in how lung cancer metastasizes, according to researchers at The University of Texas MD Anderson Cancer Center whose findings were reported in the Nov. 21 ...

A family of proteins called G proteins are a recognized component of the communication system the human body uses to sense hormones and other chemicals in the bloodstream and to send messages to cells. In work that further ...

Scientists at the Universities of York and Texas have found that a component of cancer cells, which acts like a 'cellular post office', could be the key to preventing the spread of lung cancer to other parts of the body.

The research, conducted at Queen Mary University of London (QMUL), found that a slight regulation in the length of primary cilia, small hair-like projections found on most cells, prevented the production of fat cells from ...

(Medical Xpress)A team of researchers affiliated with multiple institutions in Korea has found that genetically altering a type of bacteria and injecting it into cancerous mice resulted in the disappearance of tumors in ...

A single blood test and basic information about a patient's medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant ...

A paradigm-changing Ludwig Cancer Research study reveals that short fragments of circular DNA that encode cancer genes are far more common in cancer cells than previously believed and probably play a central role in generating ...

Studies abound that point to a role for plain old aspirin in keeping deadly cancers at bay. While aspirin is not yet part of mainstream treatment for any cancer, it is recommended by the U.S. Preventive Services Task Force ...

Cancerous tumors are voracious. Once they have consumed all the oxygen and nutrients in the original tumor site, the cancer cells travel to other parts of the body (metastasize) to find more nourishment.

A QUT-driven project has identified the way in which melanoma cells spread, opening up new pathways to treatment via drugs to 'turn off' the invasive gene.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Follow this link:
IFT20 protein's role in helping cancer cells to invade - Medical Xpress

Maggie Gets the Mother of All Surprises in This Grey’s Anatomy Sneak Peek & We’re Suddenly Worried – E! Online

Get ready to learn a little bit more about Dr. Maggie Pierce, Grey's Anatomy fans.

The cardiothoracic surgeon takes center stage this week when she finds herself on the receiving end of a surprise visit thanks to the sudden appearance of her mother (played by LaTanya Richardson Jackson) in the hospital. Well, adoptive mother, that is. You'll recall that Maggie (Kelly McCreary) is the secret love child of Dr. Webber and Meredith's mom Ellis. And if this sneak peek of Mama Pierce's arrival, exclusive to E! News, is any indication, things are going to get real awkward for Maggie real fast.

We've got to be honest, though. It's the way Mrs. Piercesorry, Dianebrushes past Maggie asking why her mom has showed up unannounced and if she's OK that has us a little worried. After all, Grey-Sloan Memorial has a slight habit of claiming its surgeons' parental units as victims shortly after they show up. Just ask Meredith's mom and step-mom, George's dad, and Alex's dad. Oh, you can'tbecause they're dead.

Elsewhere in the episode, Bailey (Chandra Wilson) hasto make a difficult decision when one of the attendings refuses to work with Eliza (Marika Dominczyk), while Stephanie (Jerrika Hinton) gets caught up in Owen (Kevin McKidd) and Amelia's (Caterina Scorsone) personal drama. Ohand we'll find out just how Alex (Justin Chambers) managed to avoid going to jail.

Are we right to be worried about Mama Pierce or are we just reading too much into things? Let us know your thoughts in the comments below!

Grey's Anatomy airs Thursdays at 8 p.m. on ABC.

See more here:
Maggie Gets the Mother of All Surprises in This Grey's Anatomy Sneak Peek & We're Suddenly Worried - E! Online

Immunology takes new approach to beating cancer – The Advocate

Two years after she was diagnosed with stage 4 lung cancer, Wanda Poche has a hard time believing she ever had the disease.

"I always felt like from the date I was diagnosed that I didn't have cancer," she said.

The 65-year-old woman is cancer-free after receiving a newly developed treatment that uses the body's immune system to fight the disease.

Immunotherapy, doctors say, is an innovative advancement that could change the way certain cancers are viewed.

"Everybody's excited about it," said Dr. Vince Cataldo, an oncologist at Mary Bird Perkins Our Lady of the Cancer Center in Baton Rouge. "We're definitely on the forefront."

Chemotherapy attacks a cancer cell's DNA to stop the cell from dividing, thereby stopping the cancer's growth. Traditional chemotherapy "tears the immune system apart," Cataldo said.

"It suppresses the immune system, and people's biggest side effects from chemotherapy are the risk of infection because there is no immune system," he said.

Immunotherapy tries to "make the immune system smarter," he said.

Normally, the body's immune system remains inactive until it needs to fight a threat. But our bodies put the brakes on the immune system to slow it down. An unchecked immune response can eventually kill you.

The new immunotherapy cancer drugs remove those brakes, Cataldo said.

"It has truly changed the way we fight multiple diseases," Cataldo said.

Some prominent drugs, like the one Poche received, target certain cancer cells to make them prone to damage from the immune system.

Cataldo explained that the cancer cells have a receptor similar to an antenna. The immunotherapy drugs block that antenna and allow the immune system to attack the cells.

Poche's battle started in October of 2014 with what she thought was a nagging sinus infection. Her doctor took a chest X-ray and found lung cancer. Because she had quit smoking decades before, Poche was surprised.

"I never expected that," she said. "All through this, I never had shortness of breath. I could always climb stairs. I've always been pretty healthy."

But her cancer had spread to her adrenal gland and lymph nodes. The ear, nose and throat doctor had saved her life, she said.

After months of different chemotherapy treatments, Poche was making no progress against the tumors. Cataldo decided she would be a candidate for a trial of a drug marketed as OPDIVO.

Poche had no side effects from the drug, which Cataldo said is common.

"It doesn't beat up the immune system," he said. "We don't normally see hair loss. We don't typically see vomiting."

After 15 months of IV infusions, there were no signs of Poche's tumors in an August scan. Last month she had a full-body scan, and the cancer had not returned.

"It was still showing clear," she said. "God is great."

Poche will take the treatments every two weeks for the foreseeable future to stop the cancer from returning. But that's a small price to pay, she said.

While immunotherapy works well for lung cancer, it doesn't treat all cancers. This class of drug has been approved to treat kidney cancer, melanoma and Hodgkin lymphoma in addition to lung cancer, diseases that "have nothing in common," Cataldo said.

But the therapy doesn't work for everyone. Patients who have autoimmune disorders like rheumatoid arthritis or lupus may experience harsh side effects.

Doctors are hopeful that more cancers can be treated with this type of drug.

"Cancer centers are looking for new indications, and they're doing cutting-edge clinical trials to see what the next one is going to be," Cataldo said.

Follow Kyle Peveto on Twitter, @kylepeveto.

Read the original:
Immunology takes new approach to beating cancer - The Advocate

Genetics of Height is Way Complex, It Turns Out – KQED

When scientists first read out the human genome 15 years ago, there were high hopes that wed soon understand how traits like height are inherited. It hasnt been easy. A huge effort to find height-related genes so far only explains a fraction of this trait.

Now scientists say theyve made some more headway. And the effort is not just useful for understanding how genes determine height, but how theyre involved in driving many other human traits.

At first, these problems didnt seem to be so complicated. The 19th-century monk Gregor Mendel discovered that traits in his garden peas, like smoothness and color, could be passed predictably from one generation to the next.

But Joel Hirschhorn, a geneticist at Boston Childrens Hospital and the Broad Institute, says it became evident that most stories of inheritance were not so simple. Height turns out to be a prime example.

Peoples height didnt behave like Mendels peas, Hirschhorn says. It wasnt like they you had two tall people and theyd either have a tall [child] or a short [child]. Often the child was partway between the parents.

Scientists explained this 100 years ago, when they realized that height was influenced by many genes, and each makes a small contribution.

So when the human genome was sequenced, scientists like Hirschhorn thought they could plumb that data to track all the height genes, and finally understand how height and in fact most other human traits are shaped by our genes.

That effort started slowly. But now, Hirschhorn says, For height there are about 700 variants known to affect height, each of them usually with a pretty small effect on height, usually like a millimeter or less.

That massive global effort has involved studying the genes of more than 700,000 volunteer subjects. Even so, the traits theyve found only explain about a quarter of the inherited height factors.

And, frustratingly, for most of those variants scientists have no idea what they actually do.

Mostly the variants crop up in mysterious bits of DNA between genes on our chromosomes. That makes it hard to figure out their roles.

So Hirschhorn and his army of colleagues, who reported on the effort last weekin the journal Nature, tried a new tack.

Their study focused only on variants that are directly in the genes themselves. By knowing that the genes do, they can understand better how variants might influence height. For example, one is in a gene that influences hormones that regulate growth.

The variants within genes are uncommon, but some have a remarkably large influence on height.

We found some that, if you carry them, you might actually be an inch taller or an inch shorter, as opposed to just a millimeter difference that we found with the previous variants, Hirschhorn says.

Scientists are still very far from identifying all the genes involved with stature, but these new findings do help them better understand the natural biochemistry that influences height.

So far most of our understanding of height has come from scientists who study children who have abnormal growth patterns, according to Constantine Stratakis, a pediatrician and scientific director of the National Institute of Child Health and Human Development.

There are rare experiments of nature that have told us these genes are involved in the regulation of growth, he says. In fact, he discovered one of those rare genes, linked to a trait called gigantism.

It leads to babies that double or triple their length in the first year of life, he says.

These natural experiments have been most useful for treating height disorders, but Stratakis hopes that eventually the genome-search methods will provide leads for future treatments.

The bigger lesson here is figuring out how the biology of a complex trait like height really works.

Rare variants can sometimes make a big difference, but most of the time its all about systems that interact that define how an organism behaves, or grows, or has a disease, develops a trait and so on, Stratakis says. And although its humbling to see the complexity, at this point its not unexpected.

Hirschhorn and his colleagues are expanding their already massive study of 700,000 subjects. That approach has drawn skepticism from some scientists, who think its a waste of effort.

David Goldstein, a professor of genetics at Columbia University, says an expanded effort could ultimately implicate every gene in existence, and that hardly helps scientists narrow down the biological factors that contribute to height.

Its likely scientists will never be able to figure out what these hundreds of common variants do to influence height, Goldstein says. Instead, a much better strategy is what Hirschhorn used in this latest study: looking for rare variants that pack a big punch.

Hirschhorn is undeterred.

We probably wont get all of the way to explaining 100 percent of the genetic factors, but in some sense thats not really our goal, Hirschhorn says. Our goal is to use the genetics to do our best at understanding the biology.

To that end, Hirschhorn and his colleagues are not just looking at height; theyre digging into traits that make people susceptible to diabetes and obesity.

The rest is here:
Genetics of Height is Way Complex, It Turns Out - KQED

Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 – Vail Daily News

Progressing at breakneck speed, genetic engineering has seen significant advancements since the first time Jamie Metzl addressed the topic at the Vail Symposium in 2015 to a sold-out audience. Metzl will return today, offering the latest update on the science and implications of this world-changing technology.

Metzl, an annual speaker at the Symposium, is a senior fellow of the Atlantic Council and an expert on Asian affairs and biotechnology policy. He previously served as executive vice president of the Asia Society, deputy staff director of the U.S. Senate Foreign Relations Committee, senior coordinator for International Public Information at the U.S. State Department, director for multilateral affairs on the National Security Council and as a human-rights officer for the United Nations in Cambodia.

Also a novelist, Metzl explores the challenging issues raised by new technologies and revolutionary science in his science fiction writing. His latest novel, Eternal Sonata, imagines a future global struggle to control the science of extreme human life extension. This world, according to Metzl, is not far off.

Jamie Metzl is a brilliant thinker and eloquent speaker who will be discussing a captivating subject based very much in reality, said Kris Sabel, Vail Symposium executive director. His background in biotechnology allows him to understand this complex science, his experience with international affairs lets him place science in a geopolitical context and his dynamic and creative mind can break it all down into digestible information for everyone

Here, Metzl elaborates on the progress of the genetics revolution, his new book, how this unique science fits into the landscape of technological breakthroughs and how the new administration may impact scientific progress.

VAIL SYMPOSIUM: What sort of progress has the genetics revolution made since you first addressed the issue in front of the Vail Symposium audience two years ago?

METZL: The genetics revolution is charging forward at a blistering, exponentially accelerating pace. Virtually every day, major progress is being made deciphering the genome; describing gene-editing tools to alter the genetic makeup of plants, animals or even humans; and outlining how gene drives can be used to push genetic changes across populations. Even if this rate of change slows, then its absolutely clear to me that these new technologies will transform health care in the short to medium term and alter our evolution as a species in the medium to long term.

VS: Despite your scholarly background on the topic, youve again chosen to use science fiction writing as a way to encompass real issues surrounding the progress in genetics science. How does your new book, Eternal Sonata, based in 2025, two years after the setting of your first genetics thriller, Genesis Code, reflect the true pace, opportunities and consequences of genetic science?

METZL: The genetic revolution is too important to be left only or even primarily to the experts. I write nonfiction articles and spend a lot of time with expert groups, but the general public must be an equal stakeholder in the dialogue about our genetic future. I aspire for my novels to be fun and exciting, but also to help people who might be a little afraid of science find a more accessible on-ramp to thinking about the many complex, challenging human issues associated with technological innovation.

I fully believe well be seeing significant growth in human health and lifespans throughout the coming decades, but this progress will also raise some thorny questions well need to address. Like Genesis Code, its based on real science and tries to explore what it will mean on a human level when new technologies begin to transform our understanding of our own mortality.

VS: How much weight should society put on concerns and opportunities of genetics science, or actually making conscious alterations to humans as a species?

METZL: Advances in genetic technologies will help us live longer, healthier, more robust lives, and we should all be very, very excited about that. Like all technologies, however, there will also be new opportunities for abuse. Thats why we need to have the broadest, most inclusive global dialogue possible to help us develop new norms and standards that can guide our actions going forward. The technologies are new, but the best values we will need to deploy to use them wisely are old.

VS: Has there, then, been any progress in policy to regulate genetics science or legal framework created to limit the radical changes this could have on society?

METZL: There is a real mismatch between the rapid pace of scientific advancement and the glacial pace of regulation. On the one hand, we dont want over-regulation killing this very promising field in its relative infancy. On the other, it is clear that all aspects of altering the human genome must be regulated. This challenge is all the greater because different countries have different belief systems and ethical traditions, so there is a deep need for a global norm-creation and then regulatory harmonization process.

VS: Do you have any insight on how changes in the administration will affect progress in this field of science?

METZL: Many people are worried about how the new administration will deal with these very complex scientific issues. Viewing genetic technologies in the context of the abortion debate would be a significant blow to this work in the United States. But the science is global, and even if the U.S. shuts down all of its labs for ideological or other reasons, then the science will advance elsewhere. Well lose our lead building the future as we wait forever for the coal mining and low-end manufacturing jobs to come back.

More:
Biotechnology xpert Jamie Metzl addresses realities of genetics revolution, Feb. 9 - Vail Daily News

The tragic story of Soviet genetics shows the folly of political meddling in science – The Conversation AU

In Soviet Russia, the science tests you.

A few years ago, one of us (Ian) was lucky enough to be invited to visit the N.I. Vavilov Institute of Plant Industry in St Petersburg, Russia. Every plant breeder or geneticist knows of Nikolai Vavilov and his ceaseless energy in collecting important food crop varieties from all over the globe, and his application of genetics to plant improvement.

Vavilov championed the idea that there were Centres of Origin (or Diversity) for all plant species, and that the greatest variation was to be found in the place where the species evolved: wheat from the Middle East; coffee from Ethiopia; maize from Central America, and so on.

Hence the Centres of Origin (commonly known as the Vavilov Centres) are where you should start looking to find genotypes the set of genes responsible for a particular trait with disease resistance, stress tolerance or any other trait you are looking for. This notion applies to any species, which is why you can find more human genetic variation in some African countries than in the rest of the world combined.

By the late 1920s, as director of the Lenin All-Union Academy of Agricultural Sciences, Vavilov soon amassed the largest seed collection on the planet. He worked hard, he enjoyed himself, and drove other eager young scientists to work just as hard to make more food for the people of the Soviet Union.

However, things did not go well for Vavilov politically. How did this visionary geneticist, who aimed to find the means for food security, end up starving to death in a Soviet gulag in 1943?

Enter the villain, Trofim Lysenko, ironically a protg of Vavilovs. The notorious Vavilov-Lysenko antagonism became one of the saddest textbook examples of a futile effort to resolve scientific debate using a political approach.

Lysenkos name leapt from the pages of history and into the news when Australias Chief Scientist, Alan Finkel, mentioned him during a speech at a meeting of chief scientists in Canberra this week.

Finkel was harking back to Lysenko in response to news that US President Donald Trump had acted in January to censor scientific data regarding climate change from the Environmental Protection Agency. Lysenkos story reminds us of the dangers of political interference in science, said Finkel:

Lysenko believed that successive generations of crops could be improved by exposing them to the right environment, and so too could successive generations of Soviet citizens be improved by exposing them to the right ideology.

So while Western scientists embraced evolution and genetics, Russian scientists who thought the same were sent to the gulag. Western crops flourished. Russian crops failed.

The emerging ideology of Lysenkoism was effectively a jumble of pseudoscience, based predominantly on his rejection of Mendelian genetics and everything else that underpinned Vavilovs science. He was a product of his time and political situation in the young USSR.

In reality, Lysenko was what we might today call a crackpot. Among other things, he denied the existence of DNA and genes, he claimed that plants selected their mates, and argued that they could acquire characteristics during their lifetime and pass them on. He also espoused the theory that some plants choose to sacrifice themselves for the good of the remaining plants another notion that runs against the grain of evolutionary understanding.

Pravda formerly the official newspaper of the Soviet Communist Party celebrated him for finding a way to fertilise crops without applying anything to the field.

None of this could be backed up by solid evidence. His experiments were not repeatable, nor could his theories claim overwhelming consensus among other scientists. But Lysenko had the ear of the one man who counted most in the USSR: Joseph Stalin.

The Lysenko vs Vavilov/Mendel/Darwin argument came to a head in 1936 at the Conference of the Lenin Academy when Lysenko presented his -ism.

In the face of scientific opinion, and the overwhelming majority of his peers, Pravda declared Lysenko the winner of the argument. By 1939, after quite a few scientists had been imprisoned, shot or disappeared, including the director of the Lenin Institute, there was a vacancy to be filled. And the most powerful man in the country filled it with Trofim Lysenko. Lysenko was now Vavilovs boss.

Within a year, Vavilov was captured on one of his collection missions and interrogated for 11 months. He was accused of being a spy, having travelled to England and the United States, and been a regular correspondent with many geneticists outside the Soviet Union.

It did not help his cause that he came from a family of business people, whereas Lysenko was of peasant stock and a Soviet ideologue. Vavilov was sent to a gulag where, tragically, he died in 1943.

Meanwhile, his collection in Leningrad was in the middle of a 900-day siege. It only survived thanks to the sacrifice of his team who formed a militia to prevent the starving population (and rats) from eating the collection of more than 250,000 types of seeds, fruits and roots even growing the potatoes in their stock near the front to ensure the tubers did not die before losing their viability.

In 1948, the Lenin Academy announced that Lysenkoism should be taught as the only correct theory, and that continued until the mid-1960s.

Thankfully, in the post-Stalin era, Lysenko was slowly sidelined along with his theory. Today it is Vavilov who is considered a Soviet hero.

In 1958, the Academy of Science began awarding a medal in his honour. The leading Russian plant science institute is named in his honour, as is the Saratov State Vavilov Agrarian University. In addition, an asteroid, a crater on the Moon and two glaciers bear his name.

Since 1993, Bioversity International has awarded Vavilov Frankel (after Australian scientist Otto Frankel) fellowships to young scientists from developing countries to perform innovative research on plant genetic resources.

Meanwhile, research here in Australia, led by ARC Discovery Early Career Fellow Lee Hickey, we are continuing to find new genetic diversity for disease resistance in the Vavilov wheat collection.

In the post-Soviet era, students of genetics and agriculture in Russia are taught of the terrible outcomes of the applications of Lysenkoism to Soviet life and agricultural productivity.

Lysenkoism is a sad and terrible footnote in agricultural research, more important as a sadly misused -ism in the hands of powerful people who opt for ideology over fact. Its also a timely reminder of the dangers of political meddling in science.

More here:
The tragic story of Soviet genetics shows the folly of political meddling in science - The Conversation AU

Fulgent Genetics to Announce Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 – GlobeNewswire (press release)

February 08, 2017 08:00 ET | Source: Fulgent Genetics, Inc.

TEMPLE CITY, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (Nasdaq:FLGT) (Fulgent Genetics or thecompany) today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, February 27, 2017 . The companys Chairman and Chief Executive Officer Ming Hsieh, its Chief Science officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host an investment community conference call the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investor section of the companys website, http://www.fulgentgenetics.com, and through a live conference call by calling 1-855-321-9535, passcode # 65226206. An audio replay will be available in the investors section of the companys website or by calling 1-855-859-2056 through March 6, 2017.

About Fulgent Genetics

Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 275 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in todays market, which enables it to provide expansive options for test customization and clinically actionable results.

Related Articles

Temple City, California, UNITED STATES

Fulgent Genetics, Inc. Logo

LOGO URL | Copy the link below

Formats available:

Continued here:
Fulgent Genetics to Announce Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 - GlobeNewswire (press release)

Wilmington volunteer recognized with 4-H state award – Port City Daily

PortCityDaily.com is your source for free news and information in the Wilmington area.

WILMINGTON 4-H volunteers from across North Carolina gathered Feb. 4 to celebrate their accomplishments through the North Carolina 4-H State Awards Recognition program. The awards ceremony was held at the Sheraton Imperial Hotel and Convention Center in Durham, N.C., and was attended by 4-H awards delegates, their families, 4-H staff members and volunteers, industry partners and sponsors.

Related reading:Communities In Schools: Changing lives one student at a time in Brunswick County

Melissa Hight of Wilmington, was recognized for outstanding service and commitment to the 4-H school enrichment program, Embryology in the Classroom. Melissa has made tremendous improvements to the program that brings fertilized chicken eggs to 2nd graders across New Hanover County. She also obtained funding from New Hanover County Farm Bureau to sponsor this program.

Melissa has brought embryology to several new schools, extending our reach to over 100 additional students this year. She also shares a lesson from the 4-H Embryology curriculum with students, going above and beyond by bringing props and energy with her. She leaves each classroom with a book about chickens and Im an EGG-cellent Kid! stickers.

These changes have taken a good program and made it great. Not only are students learning important facts about the life cycle of a chicken, they are also learning what 4-H is about and that it can be fun.

Leslie Dill serves as New Hanover Countys 4-H Agent. She received a B.A. in animal science from The Ohio State University and an M.A. in agriculture and extension education from N.C. State University. She can be reached at 910-798-7660 or leslie_dill@ncsu.edu.

4-H, the largest youth development organization in the world, is a community of seven million young people across the globe learning leadership, citizenship, and life skills. To learn more about New Hanover County 4-H, visit newhanover.ces.ncsu.edu.

-Content provided by Leslie Dill, 4-H Youth Development

This content was provided by a community member via Local Shout, a new initiative at Port City Daily. Port City Daily cannot guarantee the accuracy of information presented in this story. If you have additional information or would like to submit a story, please contact shout@portcitydaily.com.

4-H, 4H, Local Shout, Melissa Hight

Read more:
Wilmington volunteer recognized with 4-H state award - Port City Daily

Center of Excellence for Poultry Science Hosts Open House for High School, Transfer Students – University of Arkansas Newswire

Photo by Sara Landis

Keith Bramwell, extension reproductive physiologist, assists a student during an embryology workshop at the Open House hosted by the Center of Excellence for Poultry Science.

FAYETTEVILLE, Ark. The Center of Excellence for Poultry Science at the U of Arecently sponsored an Open House for high school juniors, seniorsand college transfer students. Fifty participating students came from Missouri, Texas, Oklahoma, Kansas, Illinois and Arkansas, and included prospective 3-plus-1 program transfer students from the University of Arkansas at Pine Bluff and Arkansas State University.

The 3-plus-1 Certificate of Poultry Science program allows for agriculture majors with an animal science option at UAPB to take poultry science classes at the University of Arkansas as seniors. Those courses are recognized by UAPB's School of Agriculture, Fisheries and Human Sciences, and count toward degree requirements. At the same time, those students earn a Certificate of Poultry Science from the University of Arkansas. Completion of the certificate requires 26-28 hours of poultry science credit.

The Open House provided an opportunity for prospective students to meet poultry science faculty, tour poultry science facilities and learn about the many career opportunities available with a major in poultry science. There were three workshops students participated in: Cell and Molecular Biology, Embryologyand Food Product Technology.

"The Center of Excellence for Poultry Science Open House was a real eye opening experience for our UAPB students," said UAPB interim assistant dean for academic programs and extension livestock specialist David Fernandez. "Having the abilityto physically see the opportunities they would have as part of the UAF/UAPB 3-plus-1 Poultry Science Program generated a lot of excitement and discussion about their future plans."

Students participated in the Open House and afterwardattended the Arkansas-LSU basketball game.

Editor-selected comments will be published below. No abusive material, personal attacks, profanity, spam or material of a similar nature will be considered for publication.

Continue reading here:
Center of Excellence for Poultry Science Hosts Open House for High School, Transfer Students - University of Arkansas Newswire

Chan Zuckerberg Biohub Awards $50M+ to 47 Investigators – Genetic Engineering & Biotechnology News

The Chan Zuckerberg Biohub (CZ Biohub) said today it will commit more than $50 million to fund human disease research by its first cohort of 47 investigators from the faculty of the University of California, Berkeley, Stanford University, and the University of California, San Francisco (UCSF).

Each investigator will receive a five-year appointment and up to $1.5 million toward life science research in their areas of expertise. CZ Biohub said the investigators were selected from several academic departments at the three universities, including biology, chemistry, computer science, engineering, mathematics, and physics.

An international panel of 60 scientists and engineers evaluated more than 700 applications, the Biohub said.

CZ Biohub investigators share our vision of a planet without disease. To realize this vision, we are giving some of the worlds most creative and brilliant researchers access to groundbreaking technology and the freedom to pursue high-risk research, Joseph DeRisi, Ph.D., of UCSF, co-president of the Biohub, said in a statement.

CZ Biohub investigators will challenge traditional thinking in pursuit of radical discoveries that will make even the most stubborn and deadly diseases treatable, added Dr. DeRisi, who co-leads the Biohub with Stephen Quake, D.Phil., of Stanford University.

The investigators have agreed to make their draft publications widely available through pre-print servers to ensure the rapid dissemination of research results, the Biohub said.

Open science will also be advanced, the Biohub added, through plans to establish share technology platforms where Bay Area scientists can further their research and advance efforts to fight disease.

In addition to its investigator program, the Biohub is pursuing large-scale collaborative projects that include an Infectious Disease Initiative and the Cell Atlas.

The Biohub says that its scientists and engineers will apply advanced technologies to fight against infectious diseases with research focused on four key areas: new detection technologies, new treatments, new ways to prevent infection, and new approaches to rapid response when new threats emerge.

Through the Cell Atlas project, the Biohub aims to build an international collaboration that will map the cell types of the human body. The map, which will be available to researchers worldwide, is intended to help researchers gain new insights into cell biology related to the causes of human disease, potentially leading to new therapies.

The Biohub was launched when Mark Zuckerberg and his wife, Priscilla Chan, M.D., set aside $600 million over 10 years toward a research center that will foster collaborations by professionals across multiple disciplines, including engineers, computer scientists, biologists, chemists, and other innovators.

The Biohub was one of two projects announced in September by the Chan Zuckerberg Initiative, named for the pediatrician and the Facebook founder, chairman, and CEO. The Initiative also committed $3 billion toward basic research over the next decade, with the audacious goal of curing, preventing, or managing all diseases by the end of the century.

More here:
Chan Zuckerberg Biohub Awards $50M+ to 47 Investigators - Genetic Engineering & Biotechnology News